Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

https://www.soho2020.com/

 

Leukemia
11:16

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

How I Treat Older Adults With B-ALL in 2020: Is OS Better With Blinatumomab/Inotuzumab vs. ChemoRx in R/R Disease? What Is the MRD Negativity With HCVD-Ino-Blina? Does Venetoclax Improve Response?

FEATURING Elias Jabbour
  • 21 views
  • December 22, 2020
09:43

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Adult ALL: Is There a Role for Venetoclax in ETP ALL? Does Hyper-CVAD+Nelarabine Improve OS for T-Cell Disease?

FEATURING Nitin Jain
  • 327 views
  • December 22, 2020
  • 1
12:32

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on AlloHCT in R/R ALL: Is Survival Following Post-HCT Relapse Improving? How Can MRD Monitoring Help? What Are the Options for Ph- Disease?

FEATURING Lori Muffly
  • 52 views
  • December 22, 2020
12:07

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: Are IDH Inhibitors Safe to Combine With Intensive Chemo in R/R Disease? Does Ena+Aza Combo Improve OS/EFS in Newly Diagnosed Disease?

FEATURING Stéphane De Botton
  • 13 views
  • December 21, 2020
10:08

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R AML: Is Gilteritinib Superior to Chemo in FLT3-Mutant Disease? How to Best Incorporate FLT3 TKIs?

FEATURING Catherine Smith
  • 130 views
  • December 21, 2020
  • 1
16:36

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on MRD in AML: Clonal Structures/Selection of Single Cell MRD, Enasidenib Induced Differentiation of IDH2m Cells, Defining Leukemic Clones

FEATURING Vitae Paresh Vyas
  • 10 views
  • December 21, 2020
16:25

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on COG Approach to High-Risk ALL: What Is the Best Way to Incorporate IO Into Frontline Treatment?

FEATURING Jennifer Mcneer
  • 12 views
  • December 15, 2020
13:54

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Asparaginase-Related Toxicity in AYAs With ALL: What Does Increase the Risk of Relapse? What Is the Role of TDM?

FEATURING Kjeld Schmiegelow
  • 21 views
  • December 15, 2020
18:18

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on AYAs With ALL: How to Use an MRD Result in Patients Receiving Pediatric Regimens?

FEATURING Aaron Logan
  • 19 views
  • December 15, 2020
09:34

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Acalabrutinib vs. SoC for R/R CLL: Do the Final Results of ASCEND Trial Confirm Favorable Efficacy and Safety of the BTKi Option?

FEATURING Paolo Ghia
  • 65 views
  • December 14, 2020
15:18

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on CAR-T Therapy in CLL: Are Toxicities Acceptable? What Are the MRD Rates? Does the Addition of Ibrutinib Improve Results?

FEATURING Elizabeth Shpall
  • 18 views
  • December 14, 2020
16:49

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Initial Therapy in CLL: Can We Consider BTK Inhibitors the Best Option?

FEATURING Michael Hallek
  • 80 views
  • December 14, 2020
14:36

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Treatment Consideration of CLL: Evaluation of BTK Inhibitor in the Frontline Setting

FEATURING John Byrd
  • 124 views
  • December 14, 2020
09:59

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Familial AML: What Are the Current Recommendations?

FEATURING Courtney D. DiNardo
  • 12 views
  • December 11, 2020
12:28

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Targeting Microenvironment in R/R AML: CXCR4 Inhibitors & E-Selectin Inhibition With Uproleselan

FEATURING Geoffrey Uy
  • 12 views
  • December 11, 2020
10:50

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Paradigm Changes in Newly Diagnosed AML: Is Venetoclax a Good Addition to Azacitidine? How to Prognosticate for Outcomes and Improve Them?

FEATURING Daniel Pollyea
  • 57 views
  • December 11, 2020
21:17

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Expert Q&A on AML: Familial AML, Targeting Microenvironment in R/R AM, Venetoclax + Azacitidine in Newly Diagnosed AML

FEATURING Daniel Pollyea, Geoffrey Uy, Courtney D. DiNardo
  • 32 views
  • December 11, 2020
33:39

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CAR-T for R/R AML: What Are the Current Limitations? How Can We Improve the Efficacy and Safety?

FEATURING Elizabeth Budde
  • 34 views
  • December 11, 2020
11:42

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Ven+Aza in Induction AML: Does This Combo Extend Survival Compared to SoC? What Are the Remission Rates? How High Are Adverse Events?

FEATURING Courtney D. DiNardo
  • 34 views
  • December 11, 2020
15:16

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Novel Antibodies in AML: Target Antigens, Approved Antibody Constructs (GO), Clinical Trials & Challenges to T-Cell Recruiting Antibody Constructs

FEATURING Marion Subklewe
  • 53 views
  • December 11, 2020
18:48

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Germline Mutations in AML: Who Should Be Screened? What Are the Clinical Outcomes?

FEATURING Coleman Lindsley
  • 13 views
  • December 11, 2020
09:03

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on AYA Ph- ALL: Can an Adult Hematologist Utilize a Pediatric ALL Protocol & Does It Lead to Superior Outcomes? What Does 5 yr EFS/OS Data Suggest?

FEATURING Saleem Eldadah
  • 15 views
  • December 11, 2020
14:46

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Intensive vs. Non-Intensive Approach in Adults With Ph+ ALL: Does Chemo-Free Induction / Consolidation With Dasatinib & Blinatumomab Improve OS and Induce High Rates of MRD Negativity?

FEATURING Sabina Chiaretti
  • 14 views
  • December 3, 2020
16:14

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Intensive vs. Non-Intensive Approach in Adults With Ph+ ALL: Is Intensive Chemo + BCR-ABL TKI Better Option?

FEATURING Nicholas Short
  • 17 views
  • December 3, 2020
15:40

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AlloHSCT in AML: Are There Benefits to Chemo in Older Adults? Should We Use CC-486 in the Maintenance Setting? What Are the Outcomes With Favorable Risk? Is Intensive Induction Always Necessary?

FEATURING Uma Borate
  • 118 views
  • November 13, 2020
  • 1
15:57

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on AlloSCT in AML: Which Older Patients in First Complete Remission Will Benefit From Transplantation? What Does the Molecular Risk Model Data Suggest?

FEATURING Edwin Alyea
  • 231 views
  • November 13, 2020
  • 2
18:14

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on CD123 in AML: What Determines Sensitivity and Resistance to Tagraxofusp? Does the Addition of Azacitidine Affect the Therapy?

FEATURING Andrew Lane
  • 80 views
  • November 13, 2020
22:39

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: Is Delaying Treatment Dangerous? What Are the Advantages of Ven+Aza vs. Cytotoxic Induction? How Common Is p53 Mutation?

FEATURING Laura Michaelis
  • 83 views
  • November 13, 2020
14:35

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights De-Intensified vs. Intensified Treatment in Ph+ ALL: What Are the Long Term EFS/OS Outcomes? What Is the MRD Negativity Rate With Dasatinib and Blinatumomab?

FEATURING Sabina Chiaretti
  • 13 views
  • November 13, 2020
16:00

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Ph+ ALL: What Is the Effect of CMR on OS? Is Hyper-CVAD+Ponatinib Combo Beneficial? Are Lower Intensity Regimens Promising?

FEATURING Nicholas Short
  • 161 views
  • November 13, 2020
  • 1
17:38

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: Are Venetoclax+HMA Combinations Safe and Effective? Do Combinations With Chemo/Targeted Agents Offer Clinical Benefit in R/R Disease?

FEATURING Marina Konopleva
  • 123 views
  • November 9, 2020
  • 1
18:42

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on CAR-T in ALL: What Are the Desired Characteristics of CAR-T for Adults? How Many Patients Achieve MRD Negativity? Does AUTO1 Have the Potential as a Stand-Alone Therapy?

FEATURING Martin Pule
  • 60 views
  • November 9, 2020
17:31

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R ALL: Inotuzumab Ozogamicin, Blinatumomab, & CAR T - What Are the Differences in Toxicity/Disease Burden and How to Decide Which Option Is Appropriate?

FEATURING Emily Curran
  • 33 views
  • October 30, 2020
29:00

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO CP-CML Update: How Effective Is 50mg Daily Dasatinib in Newly Diagnosed Disease? Is Asciminib Superior to Bosutinib? Does Gradual TKI Dose Reduction Improve TFR Rates?

FEATURING Michael Deininger
  • 11 views
  • October 30, 2020
17:59

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CP-CML: Can Personalization of TKI Treatment Optimize the Outcome? What Are the Current Treatment Goals?

FEATURING Delphine Rea
  • 18 views
  • October 30, 2020
15:10

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on CML: Are There Differences in Treatment Responses With Asciminib+Imatinib? What New TKIs Are Under Development?

FEATURING Jorge Cortés
  • 10 views
  • October 30, 2020
15:54

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CML-Like Disorders: Comparing Treatment Efficacy for MLN-eo, CEL-NOS, and CNL/aCML

FEATURING Nick Cross
  • 227 views
  • October 30, 2020
  • 2
10:11

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on AML: How Is Drug Development Affecting Treatment? Is Venetoclax Still Superior Than Others? Which Practices Can We Apply From MM Management? Can We Use MRD for Clinical Decisions?

FEATURING Amer Zeidan
  • 31 views
  • October 29, 2020
15:53

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on ALL: Why Does Chemo Not Work for Older Adults? Is There an Optimal Combination of Novel Agents and Chemo Intensity to Improve Outcomes?

FEATURING Marlise R. Luskin
  • 11 views
  • October 29, 2020
10:28

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Next Questions in ALL in 2020: Who Needs a Transplant and When? How to Incorporate Targeted Therapy? Can We Move Beyond Genomics?

FEATURING Selina Luger
  • 20 views
  • October 29, 2020
10:26

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Next Questions in CLL in 2020: Is Ibrutinib the Best BTK Inhibitor? Is BTK/Ven Combo Better Than Ven-Obin Alone? Will Stopping Therapy Avoid Resistance and Allow Retreatment?

FEATURING Jennifer Brown
  • 319 views
  • October 29, 2020
  • 3
12:49

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CML: Is ITH Important in CML? How Does TMB Influence Treatment Response?

FEATURING Jerald Radich
  • 7 views
  • October 27, 2020
09:02

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO ENESTnd Trial Update on Biomarkers in CML: Does Gene Expression Signature Predict Deep Molecular Response?

FEATURING Jerald Radich
  • 71 views
  • October 27, 2020
13:57

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Next Steps in CML: How Can We Improve the Success of Treatment Free Remission? What Can Be Achieved With Complete Inhibition of BCR-ABL1?

FEATURING Michael Deininger
  • 12 views
  • October 27, 2020
15:11

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Fitness in CLL: What Is the Role of Comorbidities and Age? Are Ibrutinib & Venetoclax More Beneficial in Younger Patients?

FEATURING Alessandra Tedeschi
  • 211 views
  • October 20, 2020
  • 2
15:26

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on ALL: What Is the Role of AlloSCT in Ph+ Disease? What Are the Key Elements for HSCT Indication?

FEATURING Josep-Maria Ribera
  • 12 views
  • October 20, 2020
18:20

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MRD in CLL: How Does It Correlate With Clinical Endpoints of Chemoimmunotherapy? Is FCR Combo Beneficial for PFS? What is the uMRD Rate With Venetoclax?

FEATURING William Wierda
  • 46 views
  • October 19, 2020
14:16

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on BCR Inhibitors in CLL: How Do ARQ531, LOXO-305 & Vecabrutinib Compare to Ibrutinib, Acalabrutinib & Zanubrutinib?

FEATURING Paolo Ghia
  • 92 views
  • October 19, 2020